<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We investigated the effect of <z:chebi fb="0" ids="48416">olmesartan</z:chebi> on early diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in hypertensive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> by its replacement of other <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 receptor blockers (ARBs) by <z:chebi fb="0" ids="48416">olmesartan</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The urinary albumin/<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio significantly decreased </plain></SENT>
<SENT sid="2" pm="."><plain>The present result suggests a possibility that <z:chebi fb="0" ids="48416">olmesartan</z:chebi> may have more effect on early <z:hpo ids='HP_0000112'>nephropathy</z:hpo> than other ARBs </plain></SENT>
</text></document>